OKYO Pharma Limited (OKYO)
1.02
-0.02 (-1.92%)
At close: Jan 15, 2025, 10:16 AM
Company Description
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead product includes OK-101 for the treatment of dry eye disease.
The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | GB |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Gary S. Jacob Ph.D. |
Contact Details
Address: 55 Park Lane London, GB | |
| Website | https://www.okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001849296 |
| CUSIP Number | 679345108 |
| ISIN Number | US6793451088 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer & Executive Director |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
| Michael Paul Beck | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | 6-K | Filing |
| Oct 30, 2024 | 6-K | Filing |
| Oct 23, 2024 | 6-K | Filing |
| Oct 16, 2024 | 6-K | Filing |
| Sep 10, 2024 | 6-K | Filing |
| Sep 05, 2024 | 6-K | Filing |
| Aug 27, 2024 | 6-K | Filing |
| Aug 23, 2024 | 6-K | Filing |
| Aug 23, 2024 | 6-K | Filing |
| Aug 21, 2024 | 6-K | Filing |